Overview

WAL801CL (Epinastine Hydrochloride) Dry Syrup in Paediatric Perennial Allergic Rhinitis

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to investigate the efficacy of WAL801CL Dry Syrup in comparison with ketotifen fumarate on pediatric perennial allergic rhinitis and to evaluate the safety of WAL801CL Dry Syrup compared to ketotifen fumarate and to confirm the appropriateness of dosage of WAL801 Dry Syrup.
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Epinastine
Ketotifen